The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| INBP | -13.21% | -63.99% | -18.46% | -94% |
| S&P | +13.95% | +78.35% | +12.25% | +1,033% |
Integrated BioPharma, Inc. engages in the manufacturing, distributing, marketing, and sales of vitamins, nutritional supplements, and herbal products. It operates through the following segments: Contract Manufacturing and Other Nutraceutical Businesses. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment sells private label MDC products, as well as AgroLabs products. The company was founded by E. Gerald Kay in March 1980 and is headquartered in Hillside, NJ.
No news articles found for Integrated BioPharma.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $12.69M | -6.8% |
| Gross Profit | $1.02M | -25.7% |
| Gross Margin | 8.03% | -2.0% |
| Market Cap | $9.01M | 27.7% |
| Market Cap / Employee | $58.87K | 0.0% |
| Employees | 153 | 4.1% |
| Net Income | $123.00K | -52.5% |
| EBITDA | $490.00K | -39.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.73M | 108.4% |
| Accounts Receivable | $3.98M | -9.2% |
| Inventory | 10.5 | -6.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $287.00K | -52.5% |
| Short Term Debt | $474.00K | -50.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 2.60% | 1.0% |
| Return On Invested Capital | 14.59% | -7.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.13M | 87.7% |
| Operating Free Cash Flow | $1.30M | 98.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 10.29 | 7.32 | 13.89 | 13.68 | -20.04% |
| Price to Book | 0.51 | 0.52 | 0.53 | 0.44 | 20.89% |
| Price to Sales | 0.19 | 0.18 | 0.20 | 0.17 | 21.13% |
| Price to Tangible Book Value | 0.51 | 0.52 | 0.53 | 0.44 | 20.89% |
| Price to Free Cash Flow TTM | 5.58 | 9.88 | 5.88 | 3.82 | -76.91% |
| Enterprise Value to EBITDA | 16.46 | 7.16 | 9.10 | 10.49 | 31.34% |
| Free Cash Flow Yield | 17.9% | 10.1% | 17.0% | 26.2% | 333.07% |
| Return on Equity | 4.8% | 6.4% | 4.1% | 3.4% | 50.02% |
| Total Debt | $1.32M | $1.14M | $1.02M | $761.00K | -51.16% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
